Quantcast

Apo-10’-lycopenoic acid inhibits cancer cell migration and angiogenesis and induces peroxisome proliferator-activated receptor γ

Research paper by Junrui Cheng, Benchun Miao; Kang-Quan Hu; Xueyan Fu; Xiang-Dong Wang

Indexed on: 28 Feb '18Published on: 25 Feb '18Published in: The Journal of Nutritional Biochemistry



Abstract

Publication date: June 2018 Source:The Journal of Nutritional Biochemistry, Volume 56 Author(s): Junrui Cheng, Benchun Miao, Kang-Quan Hu, Xueyan Fu, Xiang-Dong Wang Scope We have previously shown that apo-10’-lycopenoic acid (ALA), a derivative of lycopene through cleavage by carotene-9’,10’-oxygenase, inhibits tumor progression and metastasis in both liver and lung cancer animal models. The underlying mechanism remains unknown. We hypothesized that ALA inhibits cancer cell motility and angiogenesis by up-regulating peroxisome proliferator-activated receptor γ (PPARγ) which is involved in controlling angiogenesis, tumor progression and metastasis. Methods and results ALA treatment, in dose-dependent manner, was effective at inhibiting migration and invasion of liver and lung cancer cells (HuH7 and A549) in both Transwell and wound-healing models, as well as suppressing actin remodeling and ruffling/lamellipodia formation in HuH7 and immortalized lung BEAS-2B cells. ALA treatment resulted in suppression of angiogenesis in both tube formation and aortic ring assays and inhibition of matrix metalloproteinase-2 expression and activation in both HuH7 and A549 cells. Additionally, ALA dose-dependently increased the mRNA expression and protein levels of PPARγ in human THLE-2 liver cells. Conclusion ALA inhibits cancer cell motility and angiogenesis and induces PPARγ expression, which could be one of the potential mechanisms for ALA protecting against tumor progression. Graphical abstract